Blog
RSS FeedPosted by Michael Wonder on 05 Sep 2020
International reference pricing: discounts down under far surpass U.S. drug price concessions
1 September 2020 - At 30,000 feet, the view of Australia’s healthcare system does not look too different from our own ...
Posted by Michael Wonder on 19 Jul 2020
PBAC asks Roche for another comparison for Tecentriq
20 July 2020 - The submission requested a PBS (Section 100) listing for atezolizumab for use in combination with taxane chemotherapy ...
Posted by Michael Wonder on 25 Nov 2019
Medicine prices in Australia among the cheapest in the world, research shows
25 November 2019 - If you take medication for several health issues, you may be surprised to find out Australia has ...
Posted by Michael Wonder on 14 Jul 2019
Bev takes 14 pills a day. She's far from alone.
15 July 2019 - She is among the more than one-in-three Australians aged over 70 who take five or more different ...
Posted by Michael Wonder on 12 Nov 2018
PBAC shows no propensity to support Amgen's innovative method of analysis
12 November 2018 - Amgen's recent submission for blinatumomab (Blincyto) treatment of patients with B-cell precursor acute lymphoblastic leukaemia in haematological ...
Posted by Michael Wonder on 08 Aug 2018
Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?
8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...
Posted by Michael Wonder on 17 Jul 2018
Private health insurance rankings to give consumers more information about coverage and benchmarks
16b July 2018 - Private health insurance premiums will be ranked in a bid to help consumers figure out exactly ...
Posted by Michael Wonder on 09 Aug 2017
Health insurance comparison sites don’t address affordability: ombudsman
9 August 2017 - Comparison tools will not address the rising affordability concerns with health insurance, the commonwealth ombudsman has ...
Posted by Michael Wonder on 11 Oct 2016
A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK
11 October 2016 - Drug listing recommendations from health technology assessment agencies often fail to coincide with one another. ...
Posted by Michael Wonder on 19 Sep 2016
Real-world evidence: a comparison of the Australian Herceptin Program and clinical trials of trastuzumab for HER2-positive metastatic breast cancer
19 September 2016 - Estimating the real-world cost-effectiveness of a new drug relies on understanding the differences between clinical trial data ...